Programmes We Support

The Biotech Working Committee (BWC) is an inter-agency team that oversees and coordinates the biotech pipeline in Singapore, talent development, and financing efforts from the public and private sector to implement the Human Health and Potential National Biotech Strategy for Research, Innovation and Enterprise 2025 (RIE2025).

Trusted Research / Real world-data Utilisation and Sharing Tech (TRUST) is a national analytics platform that enables anonymised health-related research and real-world data to be brought together, accessed, and used in an expeditious and secure manner. The platform supports health data analytics and innovation between public institutions, and between the public and private sectors to improve health outcomes.

Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) is a translational cardiovascular research programme that integrates efforts from scientists and clinicians across multiple institutes in Singapore. Its objective is to study the mechanisms underlying cardiovascular disease progression, especially for heart failure with preserved ejection fraction, and to advance the development of therapeutics for heart failure.

The Diabetes Clinic of the Future (DCOF) programme, led by Singapore General Hospital, develops solutions using big data analytics, digital technology, behavioural economics, and natural language technologies to personalise diabetes care and improve clinical outcomes amongst Singapore patients with Type 2 diabetes.

The Cardiovascular Disease National Collaborative Enterprise (CADENCE) is a national clinical translational programme aimed at synergising cardiovascular research and technology capabilities across Singapore. It brings together the strongest basic, clinical, and translational talent and expertise across institutions – such as the National Heart Centre Singapore, National University Heart Centre Singapore, Tan Tock Seng Hospital, National University of Singapore, SingHealth Duke-NUS Medical School, Nanyang Technological University, and the Agency for Science, Technology and Research – to establish a focused and impactful national cardiovascular R&T programme with world-class peaks of excellence.

The Singapore Translational Cancer Consortium aims to create a robust framework and critical platforms to synergise cancer research capabilities across Singapore. Its member institutes include National Cancer Centre Singapore (NCCS), Cancer Science Institute of Singapore (CSI), National University Cancer Institute, Singapore (NCIS), and the Agency for Science, Technology and Research (A*STAR).

Precision Health Research, Singapore (PRECISE) coordinates the whole-of-government effort to implement Phase 2 of Singapore’s 10-year National Precision Medicine (NPM) programme. One of NPM’s objectives is to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions. The NPM programme also aims to enhance the breadth and depth of the Precision Medicine-related industries by attracting and anchoring overseas companies in Singapore, while yielding new opportunities for home-grown companies.

The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. Its vision is to be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approved products for Singapore. Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and foster the entire value chain of the cellular therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision and commercialisation by serving the healthcare, academic and industrial sectors. In addition, ACTRIS will also provide value-added services such as workforce training, regulatory facilitation and ancillary material standardisation pertaining to the delivery of cellular therapy to patients.

The Nucleic Acid Therapeutics Initiative’s mission is to build Singapore up as a world-class, regional hub for nucleic acid therapeutics (NAT) to achieve research and clinical translation excellence, strengthen resilience to future pandemics and support a vibrant local industry to deliver better long-term healthcare outcomes. NATi comprises 2 thrusts:

• NAT Exchange (NAT X), which aims to drive NAT assets into the clinic by building and developing capabilities to enable the rational design of payloads and discovering delivery platforms to address industry challenges.

• RNA Foundry, which aims to develop next-generation manufacturing technologies to support the production of formulated RNA. Partnership with industry is encouraged to co-develop and avail technologies to support asset translation and manufacturing capacities for NATi.